Protagenic Therapeutics Faces Delisting Concerns
Ticker: PTIXW · Form: 8-K · Filed: Aug 22, 2025 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 8-K |
| Filed Date | Aug 22, 2025 |
| Risk Level | high |
| Pages | 5 |
| Reading Time | 6 min |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory-filing
Related Tickers: PTIX
TL;DR
PTIX might get delisted - stock could be toast.
AI Summary
Protagenic Therapeutics, Inc. filed an 8-K on August 22, 2025, reporting a notice of delisting or failure to satisfy continued listing rules as of August 7, 2025. The company also disclosed changes in its certifying accountant and provided Regulation FD disclosures. The filing indicates potential issues with maintaining its stock exchange listing.
Why It Matters
This filing signals potential financial distress or non-compliance with exchange rules, which could lead to the company's stock being removed from trading, impacting investors.
Risk Assessment
Risk Level: high — The notice of delisting or failure to meet listing standards is a significant red flag for the company's viability and investor confidence.
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Filer of the 8-K report
- August 7, 2025 (date) — Date of earliest event reported (delisting notice)
- August 22, 2025 (date) — Date the 8-K was filed
FAQ
What specific rule or standard has Protagenic Therapeutics failed to satisfy that led to the notice of delisting?
The filing does not specify the exact rule or standard that Protagenic Therapeutics has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 7, 2025.
What other significant items are reported in this 8-K filing besides the delisting notice?
This 8-K filing also reports changes in the registrant's certifying accountant, Regulation FD disclosures, and financial statements and exhibits.
What is the SEC file number for Protagenic Therapeutics?
The SEC file number for Protagenic Therapeutics is 001-12555.
What is the ticker symbol associated with Protagenic Therapeutics?
The ticker symbol associated with Protagenic Therapeutics is PTIX.
Filing Stats: 1,593 words · 6 min read · ~5 pages · Grade level 13.5 · Accepted 2025-08-22 17:28:28
Filing Documents
- form8-k.htm (8-K) — 58KB
- ex16-1.htm (EX-16.1) — 1KB
- ex99-1.htm (EX-99.1) — 2KB
- ex99-2.htm (EX-99.2) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 641KB
- ex99-1_002.jpg (GRAPHIC) — 150KB
- ex99-2_001.jpg (GRAPHIC) — 13KB
- ex16-1_001.jpg (GRAPHIC) — 228KB
- 0001641172-25-025274.txt ( ) — 1705KB
- ptix-20250807.xsd (EX-101.SCH) — 4KB
- ptix-20250807_def.xml (EX-101.DEF) — 26KB
- ptix-20250807_lab.xml (EX-101.LAB) — 36KB
- ptix-20250807_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
Forward-looking statements can be identified by words such as "projects," "may," "will," "could,"
Forward-looking statements can be identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential," "promise" or similar references to future periods. Examples of forward-looking statements in this current report include, without limitation, statements regarding the Company's available options to resolve the deficiency and regain compliance with Nasdaq listing rules. Forward-looking statements are statements that are not historical facts nor assurances of future performance. Instead, they are based on the Company's current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties, and actual results may differ materially from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, without limitation, that there can be no assurance that the Company will file the Form 10-Q or any plan of compliance during any compliance period, that there can be no assurance that the Company will otherwise meet Nasdaq compliance standards, that there can be no assurance that Nasdaq will grant the Company any relief from delisting as necessary or whether the Company can agree to or ultimately meet applicable Nasdaq requirements for any such relief, and the other important factors described under the caption "Risk Factors" in the Company's filings with the SEC. Any forward-looking statement made by the Company in this current report is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, the Company expressly disclaims any obligation to publicly update any forward-looking statements, whether written or oral,
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROTAGENIC THERAPEUTICS, INC. Date: August 22, 2025 By: /s/ Alexander K. Arrow Name: Alexander K. Arrow Title: Chief Financial Officer 3